Research Analysts Set Expectations for MLTX FY2027 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Research analysts at HC Wainwright issued their FY2027 EPS estimates for shares of MoonLake Immunotherapeutics in a report released on Monday, March 2nd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($3.11) for the year. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.92). During the same quarter last year, the company posted ($0.72) earnings per share.

Other research analysts have also issued research reports about the company. Royal Bank Of Canada lifted their price target on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research report on Monday. UBS Group set a $24.00 target price on shares of MoonLake Immunotherapeutics in a report on Friday, January 9th. Zacks Research upgraded shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Needham & Company LLC increased their price target on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Finally, Oppenheimer lifted their price objective on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $27.85.

MoonLake Immunotherapeutics Stock Up 2.5%

MoonLake Immunotherapeutics stock opened at $18.14 on Wednesday. The company has a market capitalization of $1.17 billion, a P/E ratio of -5.15 and a beta of 1.20. The company has a debt-to-equity ratio of 0.24, a quick ratio of 9.27 and a current ratio of 9.27. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The stock has a 50-day simple moving average of $15.88 and a 200-day simple moving average of $22.28.

Insider Activity

In related news, insider Kristian Reich sold 130,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the sale, the insider owned 72,908 shares in the company, valued at $1,099,452.64. This trade represents a 64.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the transaction, the chief executive officer owned 2,948,577 shares in the company, valued at $44,464,541.16. The trade was a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 402,908 shares of company stock valued at $5,987,162 over the last three months. 12.02% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. acquired a new position in MoonLake Immunotherapeutics during the third quarter worth $509,000. Decheng Capital LLC purchased a new position in shares of MoonLake Immunotherapeutics in the second quarter valued at $8,572,000. Elevation Point Wealth Partners LLC acquired a new position in shares of MoonLake Immunotherapeutics during the 2nd quarter worth $74,000. Caitong International Asset Management Co. Ltd raised its stake in shares of MoonLake Immunotherapeutics by 22,387.5% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 84,553 shares of the company’s stock worth $606,000 after buying an additional 84,177 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter worth about $1,792,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.